Identification
- Generic Name
- Neamine
- DrugBank Accession Number
- DB04808
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Neamine (DB04808)
- Weight
- Average: 322.358
Monoisotopic: 322.185234584 - Chemical Formula
- C12H26N4O6
- Synonyms
- 2-desoxy-4-O-(2,6-diamino-2,6-didesoxy-α-D-glucopyranosyl)-D-streptamin
- 4-O-(2,6-diamino-2,6-dideoxy-α-D-glucopyranosyl)-2-deoxy-D-streptamine
- Dekamycin V
- Nebramycin X
- Negamicin
- Neomycin A
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir Neamine may decrease the excretion rate of Abacavir which could result in a higher serum level. Aceclofenac The risk or severity of nephrotoxicity can be increased when Neamine is combined with Aceclofenac. Acemetacin The risk or severity of nephrotoxicity can be increased when Neamine is combined with Acemetacin. Acenocoumarol The risk or severity of bleeding can be increased when Neamine is combined with Acenocoumarol. Acetaminophen Neamine may decrease the excretion rate of Acetaminophen which could result in a higher serum level. Acetylcholine The therapeutic efficacy of Acetylcholine can be decreased when used in combination with Neamine. Acetyldigitoxin The risk or severity of adverse effects can be increased when Neamine is combined with Acetyldigitoxin. Acetylsalicylic acid The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Neamine. Aclidinium Neamine may decrease the excretion rate of Aclidinium which could result in a higher serum level. Acrivastine Neamine may decrease the excretion rate of Acrivastine which could result in a higher serum level. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as aminocyclitol glycosides. These are organic compounds containing an amicocyclitol moiety glycosidically linked to a carbohydrate moiety. There are two major classes of aminoglycosides containing a 2-streptamine core. They are called 4,5- and 4,6-disubstituted 2-deoxystreptamines.
- Kingdom
- Organic compounds
- Super Class
- Organic oxygen compounds
- Class
- Organooxygen compounds
- Sub Class
- Carbohydrates and carbohydrate conjugates
- Direct Parent
- Aminocyclitol glycosides
- Alternative Parents
- 2-deoxystreptamine aminoglycosides / O-glycosyl compounds / Aminocyclitols and derivatives / Cyclohexylamines / Cyclohexanols / Oxanes / Monosaccharides / 1,2-aminoalcohols / Oxacyclic compounds / Acetals show 3 more
- Substituents
- 1,2-aminoalcohol / 2-deoxystreptamine aminoglycoside / Acetal / Alcohol / Aliphatic heteromonocyclic compound / Amine / Amino cyclitol glycoside / Aminocyclitol or derivatives / Cyclic alcohol / Cyclitol or derivatives show 15 more
- Molecular Framework
- Aliphatic heteromonocyclic compounds
- External Descriptors
- aminoglycoside, 2,6-dideoxy-alpha-D-glucoside (CHEBI:7489)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 5981U00LY0
- CAS number
- 3947-65-7
- InChI Key
- SYJXFKPQNSDJLI-HKEUSBCWSA-N
- InChI
- InChI=1S/C12H26N4O6/c13-2-5-8(18)9(19)6(16)12(21-5)22-11-4(15)1-3(14)7(17)10(11)20/h3-12,17-20H,1-2,13-16H2/t3-,4+,5-,6-,7+,8-,9-,10-,11-,12-/m1/s1
- IUPAC Name
- (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-{[(1R,2R,3S,4R,6S)-4,6-diamino-2,3-dihydroxycyclohexyl]oxy}oxane-3,4-diol
- SMILES
- NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O
References
- Synthesis Reference
Eiichi Akita, Tsutomu Tsuchiya, Shinichi Kondo, Shuntaro Yasuda, Sumio Umezawa, Hamao Umezawa, "1-N-((S)-.alpha.-substituted-.omega.-aminoacyl)-neamine or -ribostamycin and the production thereof." U.S. Patent US4008218, issued February, 1974.
US4008218- General References
- Not Available
- External Links
- PDB Entries
- 2et8 / 2f4s / 2fcx / 5z8k / 6e0d / 6s0v / 7cl6
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 101.0 mg/mL ALOGPS logP -2.9 ALOGPS logP -5.3 Chemaxon logS -0.5 ALOGPS pKa (Strongest Acidic) 12.66 Chemaxon pKa (Strongest Basic) 9.44 Chemaxon Physiological Charge 4 Chemaxon Hydrogen Acceptor Count 10 Chemaxon Hydrogen Donor Count 8 Chemaxon Polar Surface Area 203.46 Å2 Chemaxon Rotatable Bond Count 3 Chemaxon Refractivity 73.72 m3·mol-1 Chemaxon Polarizability 32.19 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption - 0.8567 Blood Brain Barrier - 0.9659 Caco-2 permeable - 0.7666 P-glycoprotein substrate Substrate 0.5 P-glycoprotein inhibitor I Non-inhibitor 0.7518 P-glycoprotein inhibitor II Non-inhibitor 0.8382 Renal organic cation transporter Non-inhibitor 0.8516 CYP450 2C9 substrate Non-substrate 0.8033 CYP450 2D6 substrate Non-substrate 0.8275 CYP450 3A4 substrate Non-substrate 0.6391 CYP450 1A2 substrate Non-inhibitor 0.9186 CYP450 2C9 inhibitor Non-inhibitor 0.9257 CYP450 2D6 inhibitor Non-inhibitor 0.9224 CYP450 2C19 inhibitor Non-inhibitor 0.9062 CYP450 3A4 inhibitor Non-inhibitor 0.9569 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.914 Ames test Non AMES toxic 0.6928 Carcinogenicity Non-carcinogens 0.952 Biodegradation Not ready biodegradable 0.7421 Rat acute toxicity 1.6749 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9779 hERG inhibition (predictor II) Non-inhibitor 0.8599
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created at September 11, 2007 17:49 / Updated at June 12, 2020 16:52